ArticleInternational journal of nanomedicine2011
Improved antigen cross-presentation by polyethyleneimine-based nanoparticles.
Article in International journal of nanomedicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 75 citations in OpenAlex.
- Review
- Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy.Journal of hematology & oncology · 2025Review
- Extracellular Vesicle-Inspired Minimalist Flexible Nanocapsules Assembled with Whole Active Ingredients for Highly Efficient Enhancement of DC-Mediated Tumor Immunotherapy.Advanced healthcare materials · 2024Article
- Tailoring biomaterials for vaccine delivery.Journal of nanobiotechnology · 2024Review
- Chitosan non-particulate vaccine delivery systems.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Review
- Advanced subunit vaccine delivery technologies: From vaccine cascade obstacles to design strategies.Acta pharmaceutica Sinica. B · 2023Review
- Vaccine adjuvants: mechanisms and platforms.Signal transduction and targeted therapy · 2023Review
- Enhancement of Immune Responses Elicited by Nanovaccines through a Cross-Presentation Pathway.Tissue engineering and regenerative medicine · 2023Review
- Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison.Bioactive materials · 2023Review
- Bioinspired vaccines to enhance MHC class-I antigen cross-presentation.Current opinion in immunology · 2022Review
- Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice.ACS applied materials & interfaces · 2022Article
- Vaccine adjuvants to engage the cross-presentation pathway.Frontiers in immunology · 2022Review
- Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle.Acta pharmaceutica Sinica. B · 2022Review
- Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.Journal of advanced research · 2022Article
- Cationic Nanoparticle-Based Cancer Vaccines.Pharmaceutics · 2021Review
- Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases.Advanced nanobiomed research · 2021Article
- Cationic Nanostructures for Vaccines Design.Biomimetics (Basel, Switzerland) · 2020Review
- The Role of Nanovaccine in Cross-Presentation of Antigen-Presenting Cells for the Activation of CD8Pharmaceutics · 2019Review
- Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy.Frontiers in oncology · 2018Review
- pH-Responsive Micelle-Based Cytoplasmic Delivery System for Induction of Cellular Immunity.Vaccines · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn the development of therapeutic vaccines against cancer, it is important to design strategies for antigen cross-presentation to stimulate cell-mediated immune responses against tumor antigens.
methodsWe developed a polyethyleneimine (PEI)-based protein antigen delivery system to promote cross-presentation through the major histocompatibility complex (MHC) I pathway using ovalbumin (OVA) as a model antigen. PEIs formed nanoparticles with OVA by electrostatic interactions, as demonstrated by electrophoresis analysis, scanning electron microscopy, and photon correlation spectroscopy analysis.
resultsThe nanoparticles were used to stimulate mouse bone marrow-derived dendritic cells in vitro and resulted in significantly more OVA(257-264)/MHC I complex presentation on dendritic cell surfaces. The activated dendritic cells interacted specifically with RF33.70 to stimulate interleukin-2 secretion. The cross-presentation promoting effect was more prominent in dendritic cells that had been cultured for longer periods of time (13 days). Further studies comparing the antigen presentation efficacies by other polyanionic agents, such as PLL or lysosomotropic agents, suggested that the unique "proton sponge effect" of PEI facilitated antigen escape from the endosome toward the MHC I pathway.
conclusionSuch a PEI-based nanoparticle system may have the potential to be developed into an effective therapeutic vaccine delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.